<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336365">
  <stage>Registered</stage>
  <submitdate>28/12/2010</submitdate>
  <approvaldate>19/01/2011</approvaldate>
  <actrnumber>ACTRN12611000065998</actrnumber>
  <trial_identification>
    <studytitle>The effect of zolendronic acid on the clinical resolution of acute midfoot Charcot foot</studytitle>
    <scientifictitle>The effect of zolendronic acid on the clinical resolution of acute midfoot Charcot foot</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Charcot neuroarthropathy in patients with diabetes mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients with acute Charcot foot receive either 3 intravenous infusions of placebo (normal saline) or 4mg of zolendronic acid (bisphosphonate) in 4 week intervals</interventions>
    <comparator>Placebo (normal saline)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Total immobilisation time in cast</outcome>
      <timepoint>6 months and 1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of any surgical procedures of the affected foot during the first year of follow-up. Data is collected prospectively from patient records.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with acute unilateral Charcot foot and type I or type II diabetes mellitus</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Serum creatine &gt;400 umol/l</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence>Computerized randomization</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/04/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Finland</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Pirkanmaa Hospital District</primarysponsorname>
    <primarysponsoraddress>Teiskontie 35
33521 Tampere
Finland</primarysponsoraddress>
    <primarysponsorcountry>Finland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Pirkanmaa Hospital District</fundingname>
      <fundingaddress>Teiskontie 35
33521 Tampere
Finland</fundingaddress>
      <fundingcountry>Finland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Medical School, University of Tampere</sponsorname>
      <sponsoraddress>Tesikontie
33521 Tampere
Finland</sponsoraddress>
      <sponsorcountry>Finland</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Diabetic Charcot foot is a rare but devastating foot complication of diabetes mellitus. The resolution of the acute form of Charcot foot needs immobilisation in a cast and total non-weight bearing for at least 12 to 16 weeks. Increased osteoclastic activity is thought to be one of the main pathological feature of the acute Charcot foot. That is why bisphosphonates are widely used in the treatment of acute Charcot process. There are some preliminary studies about the effect of bisphosphonates on the resolution of acute Charcot foot. In this study we investigated the effect of zoledronic acid on the clinical resolution of acute Charcot foot.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Pirkanmaa Hospital Districts Ethics Commitee</ethicname>
      <ethicaddress>Teiskontie 35
33521 Tampere
Finland</ethicaddress>
      <ethicapprovaldate>11/12/2001</ethicapprovaldate>
      <hrec>R01165M</hrec>
      <ethicsubmitdate>10/11/2001</ethicsubmitdate>
      <ethiccountry>Finland</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Toni-Karri Pakarinen</name>
      <address>Dept. of Orthopaedics and Traumatology
Teiskontie 35
33521 Tampere
Finland</address>
      <phone>+358-3-31165009</phone>
      <fax />
      <email>toni-karri.pakarinen@pshp.fi</email>
      <country>Finland</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Toni-Karri Pakarinen</name>
      <address>Dept. of Orthopaedics and Traumatology
Teiskontie 35
33521 Tampere
Finland</address>
      <phone>+358-3-31165009</phone>
      <fax />
      <email>toni-karri.pakarinen@pshp.fi</email>
      <country>Finland</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>